Skip to main content
. 2022 Nov 22;62(7):2453–2463. doi: 10.1093/rheumatology/keac661

Table 2.

Comparison of vaccination-related AEs in patients with active vs inactive SLE

Active SLE (n = 328) n (%) Inactive SLE (n = 255) n (%) Univariable
Multivariable
OR (95% CI) P OR (95% CI) P
Any AEs 277 (84.5) 207 (81.2) 0.296
Injection site pain 229 (69.8) 186 (73.0) 0.409
Minor AEs
 Any minor AEs 277 (84.5) 207 (81.2) 0.296
 Myalgia 55 (16.8) 36 (14.1) 0.382
 Body ache 74 (22.6) 46 (18.0) 0.180
 Fever 74 (22.6) 38 (14.9) 1.6 (1.1, 2.5) 0.020 1.6 (1.1, 2.5) 0.026
 Chills 37 (11.3) 29 (11.4) 0.972
 Nausea and vomiting 29 (8.8) 15 (5.8) 0.180
 Headache 84 (25.6) 63 (24.7) 0.803
 Rashes 12 (3.7) 3 (1.2) 0.060
 Fatigue 102 (31) 60 (23.5) 1.4 (1.0, 2.1) 0.043 1.5 (1.1, 2.3) 0.025
 Diarrhoea 9 (2.7) 10 (3.9) 0.427
 Abdominal pain 9 (2.7) 4 (1.6) 0.340
 Tachycardia 20 (6.0) 2 (0.8) 8.2 (1.9, 35) 0.001 8.0 (1.8, 35) 0.006
 Rise in blood pressure 5 (1.5) 3 (1.2) 0.720
 Fainting 0 (0.0) 1 (0.4) 0.256
 Difficulty in breathing 6 (1.8) 1 (0.4) 0.114
 Dizziness 26 (7.9) 15 (5.8) 0.338
 Chest pain 10 (3.0) 1 (0.4) 7.9 (1.0, 62) 0.019 7.7 (0.9, 62) 0.054
Major AEs
 Any major AEs 12 (3.7) 3 (1.2) 0.060
 Anaphylaxis 2 (0.6) 1 (0.4) 0.716
 Marked dyspnoea 1 (0.3) 0 (0.0) 0.378
 Throat closure 1 (0.3) 0 (0.0) 0.378
 Severe rashes 1 (0.3) 0 (0.4) 0.858
Hospitalization 0 (0.0) 1 (0.4) 0.256

Factors included as covariates in multivariable binary logistic regression analysis included age, gender, ethnicity, country by human development index. Bold text highlights significant P-values.

AEs: adverse events; OR: odds ratio.